Brainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary Fibrosis

• Published in the American Journal of Respiratory & Critical Care Medicine (AJRCCM), the analysis of 474 patients from Boehringer Ingelheim's Phase III INBUILD® HRCT sub-study represents the largest prospective evaluation of quantitative CT in patients with progressive pulmonary fibrosis (PPF) to date.
• Researchers used Brainomix e-Lung to assess quantitative CT measures. They found that these measures were sensitive to the effects of nintedanib from baseline to 24 weeks and 52 weeks, and associated with FVC decline at each timepoint, providing further evidence of the potential role of quantitative CT in assessing treatment response in PPF clinical trials.

OXFORD, England and CHICAGO, Oct. 1, 2026 /PRNewswire/ -- Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced new data published in the esteemed American Journal of Respiratory & Critical Care Medicine (AJRCCM), in which researchers used Brainomix e-Lung to assess quantitative CT measures. The researchers demonstrated that these measures were sensitive to the effects of antifibrotic treatment and associated with clinically relevant disease progression and treatment response in patients with progressive pulmonary fibrosis (PPF).

The study, an analysis of the INBUILD® HRCT sub-study involving 474 patients, evaluated quantitative CT measurements derived using both Brainomix e-Lung software and the University of California, Los Angeles (UCLA) research algorithm. This study is the first systematic assessment of two quantitative CT approaches on the same dataset: the UCLA QLF/QILD research algorithms in parallel with Brainomix e-Lung software. The broad consistency between the two methods provides important cross-validation of quantitative CT (qCT) for ILD clinical trials.

The researchers showed that nintedanib had significant effects on changes in e-Lung Total Disease Extent (TDE) at both 24 and 52 weeks, with significant effects also observed for e-Lung Reticulovascular Score (RVS) and Weighted Reticulovascular Score (WRVS) at week 24. The analysis also found that higher baseline quantitative CT measurements – including TDE, RVS and WRVS – were associated with a greater rate of FVC decline over 52 weeks.

Together, the findings demonstrate the potential value of quantitative CT in clinical trials: complementing conventional measures, such as FVC, by providing more sensitive and direct measures of pathological changes in the lung to stratify patients and evaluate treatment efficacy. By enabling more targeted assessment of disease progression and treatment response, quantitative CT could revolutionize the design of clinical trials focused on more sensitive and relevant mechanistic measures of disease activity, potentially accelerating the development and evaluation of new treatments for patients with PPF.

The study's lead author, Professor Anand Devaraj, Consultant Thoracic Radiologist at Royal Brompton Hospital and Medical Director at Brainomix, said: "These findings add to the growing evidence that quantitative CT can provide important information about structural lung disease that may be complementary to conventional measures such as FVC. In this analysis of patients with PPF, quantitative CT measurements were associated with subsequent disease progression and were sensitive to the effects of antifibrotic treatment. The findings support the continued development and incorporation of quantitative CT as an objective biomarker for clinical trials and, potentially, for monitoring disease progression in clinical practice."

Susanne Stowasser, MD, co-author of the study and Head of Clinical Development Pulmonology/Rheumatology at Boehringer Ingelheim International GmbH, said: "The INBUILD trial has provided important insights into the treatment of patients with progressive pulmonary fibrosis, and these new analyses demonstrate the potential value of quantitative CT as an additional measure of disease progression and treatment response. The ability to detect meaningful changes in lung structure alongside established clinical measures could help strengthen the evidence base for antifibrotic therapies and inform the design of future clinical trials."

This study has not been evaluated by FDA.

About Brainomix

Brainomix is a global pioneer in AI-powered medical imaging, transforming medical images into actionable insights to enable more precise treatment decisions in stroke and lung disease. Founded as a spinout from the University of Oxford, Brainomix brings AI-powered precision medicine into clinical practice across more than 20 countries. Its flagship Brainomix 360 Stroke platform supports acute stroke assessment throughout the patient pathway and has been shown to expand patient access to life- and disability-saving stroke treatments. Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans using a configured clinical workflow. Quantification of CT features can enable clinicians to more easily identify visual changes over multiple timepoints.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on LinkedIn.

Contacts
At the company
Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730

Media Enquiries
USA
Jordyn Temperato
LifeSci Communications
BrainomixMedia@lifescicomms.com 

UK & Europe
Sue Charles
Charles Consultants
sue@charles-consultants.com